The Japanese unit of Novartis has apologized for failing to report the side-effects of its leukemia drugs, Gleevec and Tasigna -- the second recent scandal the drugmaker has faced surrounding inappropriately-reported side-effects.
Sources report that Novartis knew about side-effects of its leukemia treatments as early as April 2013, but did not report them until April of this year.
In June, prosectors raided the Novartis Tokyo office as part of an ongoing investigation involving Novartis understating side effects of the drugmaker's Diovan hypertension pill.